Analysts’ Opinions Are Mixed on These Healthcare Stocks: OncoMed Pharma (NASDAQ: OMED), Amphastar Pharmaceuticals (NASDAQ: AMPH) and Abbott Labs (NYSE: ABT)

By Carrie Williams

Analysts have been eager to weigh in on the Healthcare sector with new ratings on OncoMed Pharma (NASDAQ: OMED), Amphastar Pharmaceuticals (NASDAQ: AMPH) and Abbott Labs (NYSE: ABT).

OncoMed Pharma (NASDAQ: OMED)

BMO Capital analyst Ian Somaiya reiterated a Buy rating on OncoMed Pharma (NASDAQ: OMED) yesterday and set a price target of $18. The company’s shares closed yesterday at $9.64.

According to TipRanks.com, Somaiya is a 5-star analyst with an average return of 16.0% and a 62.7% success rate. Somaiya covers the Healthcare sector, focusing on stocks such as Aeglea Biotherapeutics Inc, Corcept Therapeutics Inc, and Protagonist Therapeutics.

Currently, the analyst consensus on OncoMed Pharma is Strong Buy and the average price target is $16.33, representing a 69.4% upside.

In a report issued on March 8, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $16 price target.
Amphastar Pharmaceuticals (NASDAQ: AMPH)

In a report released yesterday, Gary Nachman from BMO Capital reiterated a Hold rating on Amphastar Pharmaceuticals (NASDAQ: AMPH), with a price target of $16. The company’s shares closed yesterday at $14.74.

According to TipRanks.com, Nachman is a 4-star analyst with an average return of 12.8% and a 63.0% success rate. Nachman covers the Healthcare sector, focusing on stocks such as Sucampo Pharmaceuticals, Pacira Pharmaceuticals, and Zimmer Biomet Holdings.

Amphastar Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $19.50.

Abbott Labs (NYSE: ABT)

Abbott Labs (NYSE: ABT) received a Hold rating from BMO Capital analyst Joanne Wuensch yesterday. The company’s shares closed yesterday at $45.53, close to its 52-week high of $45.84.

According to TipRanks.com, Wuensch is a 5-star analyst with an average return of 10.9% and a 75.0% success rate. Wuensch covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Zimmer Biomet Holdings, and Baxter International.

Abbott Labs has an analyst consensus of Strong Buy, with a price target consensus of $49.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.